23 results about "Bacterial vaccine" patented technology

The invention discloses a method for detecting the content of monosaccharide components in bacterial capsular polysaccharide or a conjugate thereof, and belongs to the field of biological product detection. Taking pneumococcus as an example, different hydrolysis methods are adopted for different serotypes of capsular polysaccharides, connected glucosidic bonds are broken through hydrolysis, released monosaccharide components and 1-phenyl-3-methyl-5-pyrazolone are subjected to derivatization under the alkaline condition to generate derivatives with ultraviolet absorption, and then the capsular polysaccharides with different serotypes are obtained. And then detecting the composition and the content of each monosaccharide generated by polysaccharide hydrolysis through liquid chromatography. According to the method, each monosaccharide component can be quickly and effectively hydrolyzed, meanwhile, various polysaccharides with different structural characteristics can be separated and detected by adopting a derivatization method, whether the monosaccharide composition of each serotype polysaccharide accords with a theoretical structure or not can be qualitatively analyzed, and the content of each monosaccharide component can be quantitatively determined to calculate the content of the polysaccharides; and a better technical support is provided for quality control of the antigen component capsular polysaccharide of the bacterial vaccine.

The present document discloses a method for producing a bacterial vaccine composition against bacterial diseases in animals, such as tetrapods or fish, wherein said bacterial vaccine composition comprises inactivated bacteria of the bacterium causing said bacterial diseases. The method involves exposing the bacteria to different growth conditions and then preparing a bacterial vaccine composition where the bacteria are exposed to different growth conditions. With vaccines prepared by the present method, bacterial diseases that previously had not been able to be cured could be treated or the effect of the treatment was more long-lasting.

Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated carrier proteins. The glycosylated carrier proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated carrier proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated carrier proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.

The invention discloses a DC (dendritic cell) capture type engineering bacterial vaccine for realizing cytoplasm antigen transfer by utilizing gap connection, which is characterized in that attenuated salmonella VNP20009 is utilized to simultaneously express Antigen 4T1-M8 and DC capture peptide CBP-12 to increase contact so as to enhance formation of gap connection between tumor cells and DC and promote delivery of antigen to DC cytoplasm, so that MHC-I mediated cross presentation is enhanced. In addition, as an intracellular bacterium, the VNP20009 can infect tumor cells and colonize in the tumor cells. Therefore, the tumor antigen carried by the VNP20009 can be expressed in cells, so that the tumor antigen can be presented to the surfaces of tumor cells by MHC-I as an endogenous antigen to be recognized by specific CD8 + T cells.

The invention is directed to compositions and methods for the stabilization of viral and bacterial vaccines. Vaccines of the invention are contained in VLPs with stabilizing agents such as, for example, sugar alcohols (e.g., sorbitol) and degraded gelatins. Preferably the gelatin has an average molecular weight of 10,000 kilodaltons or less. These vaccines have a substantially improved thermostability as well as long term stability. The invention is also directed to the manufacture of a vaccine or the invention and methods for the administration of a vaccine of the invention to patients.

The invention relates to a vaccine freeze-drying protective agent as well as a preparation method and application thereof, and belongs to the technical field of biological medicines. The vaccine freeze-drying protective agent is prepared from the following raw materials: trehalose, mannitol, arginine, pullulan, 2-hydroxypropyl-beta-cyclodextrin, phospholipid, sodium sulfite and a protective additive, the protective additive is at least one of hydroxyl ectoine, betaine, dodecyl dimethyl betaine and polycarboxylic acid betaine. The preparation method comprises the following steps: shearing and mixing the 2-hydroxypropyl-beta-cyclodextrin and the phospholipid at a high speed, sequentially adding the other components, adjusting the pH and osmotic pressure, performing sterile filtration, and performing freeze drying. The protective agent can effectively inhibit phase separation, sugar recrystallization and interfacial adsorption in the freeze-drying process, significantly improves the activity retention rate and physical stability of vaccines in the freeze-drying and storage periods, and is suitable for preparing freeze-drying preparations of various vaccines such as viral vaccines, bacterial vaccines and recombinant protein vaccines.

A vaccine comprising a live avirulent strain of bacteria or an immunogenic composition that comprises a live avirulent strain of bacteria, wherein the bacteria is cured of plasmids and / or transposons that contain AMR genes, and a non-conjugative synthetic curing plasmid that cures plasmids and / or transposons that contain AMR genes from such bacteria. A method for producing the live avirulent strain of bacteria or an immunogenic composition that comprises a live avirulent strain of bacteria; a method for treating, preventing, or reducing the severity, duration, or incidence of clinical signs, of a virulent bacterial infection; and a method for preventing, or reducing the risk or incidence of transference of AMR genes are also disclosed.

The present invention discloses a non-pathogenic Escherichia coli isolate expressing only F4 fimbriae adhesin and its application. The growth rate of the strain of the present invention is similar to that of the standard reference strain C83902 of F4ac+ enterotoxigenic Escherichia coli, and it exhibits good adhesion to the small intestinal epithelial cells of piglets in vitro experiments. Immunizing mice with the fimbriae adhesin extract extracted from the isolate or immunizing piglets with the inactivated vaccine prepared based on the isolate can induce the production of high-titer anti-FaeG antibodies, and the obtained immune piglet serum significantly inhibits the adhesion of the F4ac+ETEC domestic reference strain C83902 strain to IPEC‑J2 cells. The non-pathogenic Escherichia coli isolate is expected to become a candidate live vaccine strain for preventing diarrhea in piglets caused by infection with enterotoxigenic Escherichia coli expressing F4 fimbriae adhesin.

The present application relates to a vaccine freeze-drying protective agent, its preparation method and application, and belongs to the technical field of biological medicine. The vaccine freeze-drying protective agent comprises the following raw materials: trehalose, mannitol, arginine, pullulan, 2-hydroxypropyl-beta-cyclodextrin, phospholipid, sodium sulfite and a protective additive; the protective additive is at least one of hydroxyectoin, betaine, dodecyl dimethyl betaine and polycarboxylic betaine. The preparation method comprises the following steps: mixing 2-hydroxypropyl-beta-cyclodextrin and phospholipid by high-speed shearing, sequentially adding the remaining components, adjusting pH and osmotic pressure, and then performing freeze-drying after sterile filtration. The protective agent can effectively inhibit phase separation, sugar recrystallization and interface adsorption during the freeze-drying process, significantly improve the activity retention rate and physical stability of the vaccine during freeze-drying and storage, and is suitable for the preparation of freeze-drying preparations of various vaccines such as viral vaccines, bacterial vaccines and recombinant protein vaccines.

Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated proteins. The glycosylated proteins may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. The glycosylated proteins may be synthesized in cell-free glycoprotein synthesis (CFGpS) systems using prokaryote cell lysates that are enriched in components for glycoprotein synthesis such as oligosaccharyltransferases (OSTs) and lipid-linked oligosaccharides (LLOs) including OSTs and LLOs associated with synthesis of bacterial O antigens.

The present document discloses a method for producing a bacterial vaccine composition against bacterial diseases in animals, such as tetrapods or fish, wherein said bacterial vaccine composition comprises inactivated bacteria of the bacterium causing said bacterial diseases. The method involves exposing the bacteria to different growth conditions and then preparing a bacterial vaccine composition where the bacteria are exposed to different growth conditions. With vaccines prepared by the present method, bacterial diseases that previously had not been able to be cured could be treated or the effect of the treatment was more long-lasting.

The present invention relates to vaccines and vaccine compositions, in particular vaccines and vaccine compositions inactivated with antibiotics or antibacterial compounds. In particular, the invention extends to a bacterial vaccine or vaccine composition wherein the bacteria has been inactivated by an antibiotic or an antibacterial compound. The invention further extends to the use of the vaccine and vaccine compositions as a therapeutic or as part of a vaccine in the prevention of infection with a bacterial infection, such as Bordetella pertussis, and the treatment and / or prophylaxis of bacterial diseases, such as pertussis disease (whooping cough).

Bacterial vaccine vectors, cell cultures, immunogenic compositions, and methods for stimulating an immune response against Porcine Circovirus Type 2 (PCV2) infection in a host animal susceptible to infection by PCV2. Vaccine vectors comprising a recombinant bacterium comprising a nucleic acid encoding a conserved PCV2 capsid protein, which is configured to self-assemble, after expression, into a non -infectious PCV2 virus-like particle to stimulate an immune response against PCV2 infection in a host animal susceptible to infection by PCV.

The invention discloses a preparation method and application of a visual synergistic bacterial vaccine. According to the vaccine, a key pathogenic bacterium is used as a mode antigen, alpha-Al2O3 is used as an immunologic adjuvant, and genipin is used as an imaging agent, so that the visual synergistic bacterial vaccine is prepared. According to the vaccine, a mode antigen-mediated specific immune response activation function, an alpha-Al2O3-mediated cellular immunity enhancement function and a genipin-mediated protein cross-linking and imaging function are fully exerted. Through a mucous membrane drug delivery mode, the immunologic reprogramming kit can be used for immunologic reprogramming of periodontitis microenvironment.

The invention provides a bacterial vaccine for resisting recurrence of bacterial infection, the bacterial vaccine comprises polydopamine and a specific photo-thermal bactericide, the specific photo-thermal bactericide is used for killing bacteria, the polydopamine is used for in-situ enrichment of antigens to trigger immune reaction, and the antigens are killed bacteria. The invention also provides an antigen-enriched nanoparticle which comprises a Prussian blue nanoparticle core, a polydopamine coating and an erythrocyte membrane, the outer surface of the Prussian blue nanoparticle core is coated with polydopamine, so that the polydopamine coating is formed on the outer surface of the Prussian blue nanoparticle, and the erythrocyte membrane is coated with the polydopamine coating. The erythrocyte membrane is coated with the polydopamine coating grafted with the targeting peptide. The invention also provides application of the bacterial vaccine or the antigen-enriched nanoparticles in preparation of a biomedical material for treating skin infection or preparation of a biomedical material for preventing recurrence of bacterial infection and a preparation method of the bacterial vaccine or the antigen-enriched nanoparticles. The nanoparticles can promote elimination of skin infectious abscess and reduce the recurrence risk of MRSA infection.

The invention discloses a bacterial holoantigen-loaded PLGA (poly (lactic-co-glycolic acid)) microsphere vaccine as well as a preparation method and application thereof. The method comprises the following steps: cracking target bacteria by adopting a bacterial cell protein lysis solution to obtain whole-bacterial antigens, and preparing whole-bacterial antigen particles in a nanoparticle form in a high-pressure co-extrusion manner; the antigen particles and a PLGA microsphere carrier are mixed through a multiple emulsion method, and a microsphere vaccine (MSV) with antigens loaded inside and outside the carrier can be obtained. The antigen on the surface of the MSV is released in a burst release manner, and the antigen loaded in the MSV can achieve a long-acting slow release effect, so that the programmed step-by-step release control of the antigen release behavior is realized, that is, the dual effects of primary immunization and enhanced immunization can be achieved by single-dose vaccine injection. In addition, the MSV can effectively avoid damage of bacterial toxins to immune cells of the body, and the biological safety of bacterial vaccines is improved. The design is reasonable, and the introduction of the microsphere preparation provides a safe and reliable carrier platform for a bacterial inactivated vaccine.

The invention belongs to the technical field of biological medicine, and particularly relates to polyamino acid, polyamino acid nanoparticles, a polyamino acid engineered bacterial vaccine and a preparation method. The polyamino acid provided by the invention has a structure as shown in formula (I). The polyamino acid provided by the invention can be prepared into nano particles and further prepared into bacterial vaccines. Nanoparticles prepared from the polyamino acid provided by the invention can have good monodispersity, have amino-terminated groups and rich positive charges on the surfaces, can be grafted on the surfaces of bacteria in an amide condensation manner, and then are used as vaccines by efficiently loading different antigens through electrostatic adsorption; the polyamino acid engineered bacterial vaccine prepared from the nanoparticles has no toxic or side effect on human bodies, has the function of promoting activation of antigen presenting cells, can promote maturation of dendritic cells in vivo and further initiate strong adaptive immune response, and has a good immune activation effect. Formula (I).

The invention belongs to the technical field of bacterial vaccines, particularly relates to a sodium alginate-coated inactivated vaccine capable of retaining metabolic activity, and further discloses a preparation method and application of the sodium alginate-coated inactivated vaccine. The sodium alginate-coated inactivated vaccine capable of retaining metabolic activity, disclosed by the invention, is prepared under a low-temperature condition, so that the obtained inactivated vaccine capable of retaining metabolic activity has higher metabolic activity. By wrapping sodium alginate (Alg) on the surface of the inactivated vaccine strain retaining metabolic activity, the stability of the vaccine in a gastric acid environment is further improved.

Disclosed are methods, systems, components, and compositions for cell-free synthesis of glycosylated proteins, which may be utilized in vaccines, including anti-bacterial vaccines. The glycosylated proteins may include a bacterial polysaccharide conjugated to a carrier, which may be utilized to generate an immune response in an immunized host against the polysaccharide conjugated to the carrier. Suitable carriers may include but are not limited to Haemophilus influenzae protein D (PD), Neisseria meningitidis porin protein (PorA), Corynebacterium diphtheriae toxin (CRM 197), Clostridium tetani toxin (TT), and Escherichia coli maltose binding protein, and variants thereof.

The invention discloses a vaccine composition which comprises a bacterial antigen and at least one drug carrier, the drug carrier is a saponin-containing polymer microsphere which is formed by freezing and thawing a polymer microsphere with a cavity structure so as to form an opening or a pore on the surface of the polymer microsphere, the preparation method of the vaccine composition comprises the following steps: mixing the drug carrier with a solution containing bacterial antigens, preferably enabling the bacterial antigens to be loaded on the drug carrier in modes of infiltration and / or adsorption and the like, and then centrifuging to remove supernate so as to obtain the polymer microspheres loaded with the antigens.

The invention provides a method for detecting the size of polysaccharide molecules of a multivalent bacterial vaccine, which is characterized by comprising the following steps in sequence: 1) providing a mixed solution of bacterial polysaccharides containing various serotypes; 2) performing a gel filtration method on the mixed solution to obtain a continuously collected multi-tube eluent; and 3) carrying out rate turbidimetry on the multi-tube eluent to obtain the amount of each type of bacterial polysaccharide in each tube, and respectively obtaining the KD value of each type of bacterial polysaccharide according to the amount of each type of bacterial polysaccharide. According to the method, the detection efficiency of the molecular size of the bacterial polysaccharide is greatly improved, the operation is simple, sensitive and accurate, the automation degree is high, and a guarantee is provided for research, development, production and quality control of bacterial vaccines.

The present disclosure pertains to an avian vaccine that includes a plurality of electron beam (eBeam) -treated bacteria. The present disclosure also pertains to methods of immunizing an avian subject by administering an avian vaccine of the present disclosure to the avian subject. The present disclosure also pertains to methods of making an avian vaccine of the present disclosure by exposing a plurality of bacteria to eBeam treatment.